Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Lingang Centre, marking its official establishment in the Lingang Investment Holding Group Park. This wholly-owned subsidiary will primarily handle two domestic products focusing on hepatitis and anti ...

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...

GSK announced positive Phase II results for its mRNA seasonal influenza vaccine, showing strong immune responses against ...